Skip to main content

Advertisement

Table 2 Subjective measures assessed by visual analogue scale (0–100 mm)

From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Parameters Baseline (n = 16) 6 weeks (n = 15) 10 weeks (n = 13) 18 weeks (n = 14) 32 weeks (n = 11)
Fatigue 55 ± 21 46 ± 30 44 ± 28 45a ± 22 41a ± 29
Pain 49 ± 28 31 ± 32 32 ± 29 39 ± 25 34 ± 26
Patient assessmentb 62 ± 29 38a ± 30 49 ± 23 48a ± 31 40a ± 28
Physician assessmentc 56 ± 16 30a ± 22 36a ± 14 31a ± 20 26a ± 12
  1. Results are given in mean ± standard deviation. aDenotes statistical significance of the observed median change-from-baseline value with P ≤ 0.05 by Wilcoxon signed rank test. bPatient self-assessment of overall well-being. cPhysician global assessment of patient's overall well-being.